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he interaction between doctors and the p
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TIt is in doctors’ and the drug industry’s best interests that their interactions be openly declaredThere is no such thing as a free lunch. Pharmaceutical compa-
nies lavish meals, five-star travel, cash and gifts on doctors for
one reason: to encourage them to prescribe their drugs. The
standard retort from the medical profession is that doctors have
sufficient clinical objectivity — and personal integrity — not to
be so crudely swayed. Perhaps so.1
harmaceutical
lic domain by
n The Austral-
e pharmaceu-
ydney.2 What
regarding the
extent of hospitality provided by pharmaceutical companies to
doctors, but the response of the Australian Medical Association
(AMA). The AMA’s public stance was that pharmaceutical industry
sponsorship of accommodation and restaurant meals is perfectly
acceptable, that drug company sponsorship serves to “oil the
wheels” of medical education, and that industry-sponsored events
provide valuable opportunities for doctors “to critically question
the companies’ products” and that “no patient harm comes from
this practice”.2 A review of the literature, however, suggests that
this is not true.3,4
The Australian Competition and Consumer Commission
(ACCC) had a differing view. Following the recent release of the
ACCC’s revised guidelines for disclosure of industry support, the
Chairman of the ACCC noted that “Consumers should be able to
have confidence that decisions made by their doctors are made
solely having regard to their best interest without any potential for
influence by benefits or perks”.5 Stated in these terms, the issue is
not so much the pharmaceutical industry itself, but the preven-
tion, assessment and management of conflict of interest and, more
fundamentally, the importance of public trust in doctors.
The moral core of medicine and the therapeutic relationship has
always been expressed in terms of the possession and expression of
values such as honesty, integrity, benevolence, respect, compassion,
courage and trustworthiness. Trust, which in relation to health care
may denote faith, commitment, respect, belief and confidence, has
been the focus of extensive academic exploration by a broad range
of writers.6-10 All have pointed to the centrality of trust in
therapeutic relationships, the “non-legal” expression of trust, the
specific and contextual nature of trust and the manner in which
trust can be threatened, diminished or destroyed by actions or
behaviour including professional incompetence, abuses of power,
boundary violations, experience of harm or the lack of care or
respect, deception and manifest conflicts of interest.11 Of those things
that may damage trust in doctors, much of the attention in recent
years has been on recognising and managing conflict of interest.
What then constitutes a conflict of interest and how may we
avoid it occurring?
Although medical codes of ethics and statements of medical
professionalism often give the impression that doctors have a
single higher duty to care for the sick, in reality, the relationships
that doctors have with their patients are determined by multiple
interests, many of which may influence care or decision making.
Doctors may hold patient care as their highest professional ideal,
but they may also be concerned with community welfare, partici-
pation in research, career advancement, student teaching, contin-
ued employment, public or professional recognition, and the
obligations they have to their care for themselves and their
families. While it is inevitable that doctors will have multiple
interests, true conflicts of interest (a set of conditions in which
professional judgement concerning a primary interest, such as a
patient’s welfare, is unduly influenced by a secondary interest,
such as financial gain) are neither inevitable nor common.12 But
distinguishing where there are no conflicts between these interests
from where there is a genuine conflict of interest is sometimes
difficult, as any assessment of behaviour must take into account
the ethical standards of the profession, the nature of the relation-
ship in question, and the values of the community within which it
occurs. What makes this assessment even more difficult is that
standards of doctors’ behaviour may change as a consequence of
deeper sociocultural changes, and according to changes in profes-
sional interests, and changes in public or patient needs and
expectations. This means that the only way to establish that a
conflict of interest exists is to have all the relevant facts available
for scrutiny by the participants in the relationship, and by the
community or an independent third party. This is only possible if
there is a genuine commitment to disclosure and transparency in
all areas of medical practice.
Unfortunately, a review of the history of medicine suggests that
the medical profession has, until recently, generally been reluctant
to be exposed to public scrutiny, either out of fear of legal or social
repercussions that may result from such disclosure, or on the
grounds that that there is no need for it or no public desire for it.
Although such concerns may be understandable, for the most part
they are unfounded. Transparency and honest disclosure may
actually reduce loss of trust, formal and informal complaints and
litigation, and it is the culture of secrecy and sense of moral
superiority that sometimes runs through the health professions,
rather than “unnecessary” exposure to a disinterested public, that
threatens public trust and undermines the doctor–patient or
researcher–patient relationship. In this regard, it is of note that a
recent randomised trial in the United States of disclosing doctors’
financial incentives to patients found that patients’ trust in their
doctors was unharmed, and their loyalty to their doctor’s practice
was strengthened.13
Therefore, it is hard to disagree with the ACCC that there is merit
in increasing the degree to which the relationships between doctors
and the pharmaceutical industry are transparent. It may, as has
been claimed, ultimately prove to be the case that these relation-
ships do not give rise to conflicts of interest and that the ACCC’s
new reporting requirements are excessive or unreasonable, but at
this stage we do not know that this is true, and we have ample
evidence that interaction with industry can create complex andMJA • Volume 185 Number 6 • 18 September 2006 299
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ing, formulary requests, attitudes and knowledge regarding phar-
maceuticals and therapeutics, and the design and interpretation of
research.14 In light of this, it is in doctors’ and the industry’s best
interests that their interactions be openly declared in the relevant
context. This will enable informed public and professional consid-
eration of the legitimacy of each group’s interest and determination
of whether a conflict of interest exists and what measures should be
taken to deal with it.
There are many means for encouraging transparency, respon-
sibility and accountability in health care, including the incorp-
oration of ethics in medical education; support for inquiries into
professionalism and trust; introduction of templates for disclo-
sure of secondary interests in the research and clinical setting;15
development and compliance with codes of ethics by the major
medical colleges and industry groups; incorporation of patients’
representatives and conflict of interest committees into hospi-
tals; and establishment of health care complaints commissions
by government. All are deserving of support, even though
currently there are insufficient data to evaluate the effect of most
such interventions.
Given what we know about the fragility of trust in medicine
and the interaction between doctors and the pharmaceutical
industry, the profession should support moves to increase disclo-
sure. Even though disclosure may not, in itself, reduce the
frequency of unethical behaviour or relationships, and may have
no effect on public awareness, it is impossible to adequately
identify, manage or prevent conflicts of interest if doctors, the
peak bodies that represent them, and the industry groups with
which they deal are not completely open about their interactions.
Claims that the medical profession is not subject to influence,
that the possibility of conflicts of interest arising in relationships
between doctors and the pharmaceutical industry does not exist,
and that disclosure requirements will lead to the collapse of
continuing medical education are naïve, unfounded, inappropri-
ate, and counterproductive.
Doctors occupy a unique position of trust in society. They
should act solely in the best interests of the patient — as many
do. But drug companies spend billions of dollars on promotions
because they work. The medical profession cannot have it both
ways. If doctors want to be seen to be beyond influence, the
remedy is simple. Be willing to say thanks, but no.1
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